Assignee
BioNTech SE
DE·48 granted patents·93 pending applications·58 citations·filing 2014–2025
Top patents by PatentIndex Score
141 records- 0194US11547673B1Coronavirus vaccineBioNTech SE·Filed 2021·Granted Jan 10, 2023·12 cites·45 claims
- 0292US11878055B1Coronavirus vaccineBioNTech SE·Filed 2023·Granted Jan 23, 2024·2 cites·30 claims
- 0392US11779659B2RNA constructs and uses thereofBioNTech SE·Filed 2021·Granted Oct 10, 2023·4 cites·22 claims
- 0490US12059498B2Preparation and storage of liposomal RNA formulations suitable for therapyBioNTech SE·Filed 2021·Granted Aug 13, 2024·3 cites·26 claims
- 0589US11925694B2Coronavirus vaccineBioNTech SE·Filed 2022·Granted Mar 12, 2024·1 cites·36 claims
- 0689US11559587B2RNA formulation for immunotherapyBioNTech SE·Filed 2019·Granted Jan 24, 2023·3 cites·44 claims
- 0789US11395799B2Preparation and storage of liposomal RNA formulations suitable for therapyBioNTech SE·Filed 2018·Granted Jul 26, 2022·7 cites·31 claims
- 0889US11222711B2Predicting immunogenicity of T cell epitopesBioNTech SE·Filed 2014·Granted Jan 11, 2022·11 cites·34 claims
- 0989US2026085126A1Agonistic tnf receptor binding agentsBioNTech SE·Filed 2025·Application pending·0 cites
- 1088US11987569B2Substituted imidazoquinolines as agonists of TLR7BioNTech SE·Filed 2022·Granted May 21, 2024·1 cites·16 claims
- 1187US12421319B2Binding agents that bind OX40 (CD134) and method of use thereof to treat diseaseBioNTech SE·Filed 2023·Granted Sep 23, 2025·0 cites·11 claims
- 1287US12270813B2Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapyBioNTech SE·Filed 2018·Granted Apr 8, 2025·2 cites·26 claims
- 1387US12054485B2Substituted imidazoquinolinesBioNTech SE·Filed 2022·Granted Aug 6, 2024·1 cites·8 claims
- 1487US11951185B2RNA constructs and uses thereofBioNTech SE·Filed 2021·Granted Apr 9, 2024·1 cites·49 claims
- 1586US11267813B2Substituted imidazoquinolinesBioNTech SE·Filed 2018·Granted Mar 8, 2022·3 cites·4 claims
- 1686US2026049112A1Tumor Antigens for Determining Cancer TherapyBioNTech SE·Filed 2025·Application pending·0 cites
- 1786US2025242059A1Coronavirus vaccineBioNTech SE·Filed 2024·Application pending·0 cites
- 1885US12460198B2Method for reducing immunogenicity of RNABioNTech SE·Filed 2023·Granted Nov 4, 2025·0 cites·19 claims
- 1984US2024124609A1Human monoclonal antibodies to ganglioside gd2BioNTech SE·Filed 2023·Application pending·0 cites
- 2083US12385049B2Modification of RNA, producing an increased transcript stability and translation efficiencyBioNTech SE·Filed 2022·Granted Aug 12, 2025·0 cites·30 claims
- 2183US2024390524A1Rna constructs and uses thereofBioNTech SE·Filed 2024·Application pending·0 cites
- 2281US12133899B2Coronavirus vaccineBioNTech SE·Filed 2022·Granted Nov 5, 2024·0 cites·24 claims
- 2380US12410221B2Tumor antigens for determining cancer therapyBioNTech SE·Filed 2023·Granted Sep 9, 2025·0 cites·13 claims
- 2480US11504419B2Individualized vaccines for cancerBioNTech SE·Filed 2018·Granted Nov 22, 2022·1 cites·33 claims
- 2580US2025011797A1Stabilization of poly(a) sequence encoding dna sequencesBioNTech SE·Filed 2024·Application pending·0 cites
- 2679US12208136B2Coronavirus vaccineBioNTech SE·Filed 2023·Granted Jan 28, 2025·0 cites·28 claims
- 2779US11046745B2Peptide mimotopes of the CD3 T-cell co-receptor epsilon chain and uses thereofBioNTech SE·Filed 2015·Granted Jun 29, 2021·3 cites·38 claims
- 2879US2026071201A1Methods for Providing Single-Stranded RNABioNTech SE·Filed 2025·Application pending·0 cites
- 2978US2025283888A1Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapyBioNTech SE·Filed 2024·Application pending·0 cites
- 3077US2022257783A1Recombinant vaccines and use thereofBioNTech SE·Filed 2022·Application pending·0 cites
- 3176US11760809B2Human monoclonal antibodies to ganglioside GD2BioNTech SE·Filed 2020·Granted Sep 19, 2023·0 cites·10 claims
- 3276US11279684B2Substituted imidazoquinolines as agonists of TLR7BioNTech SE·Filed 2018·Granted Mar 22, 2022·1 cites·15 claims
- 3376US2025108008A1Preparation and storage of liposomal rna formulations suitable for therapyBioNTech SE·Filed 2024·Application pending·0 cites
- 3475US12378531B2Use of RNA for reprogramming somatic cellsBioNTech SE·Filed 2021·Granted Aug 5, 2025·0 cites·9 claims
- 3575US2023406902A1Peptide mimotopes of claudin 18.2 and uses thereofBioNTech SE·Filed 2023·Application pending·0 cites
- 3674US11814411B2Nucleic acid molecules encoding binding agents to CD40 and 4-1BB (CD137)BioNTech SE·Filed 2021·Granted Nov 14, 2023·0 cites·14 claims
- 3773US12186387B2Coronavirus vaccineBioNTech SE·Filed 2022·Granted Jan 7, 2025·0 cites·28 claims
- 3873US2024366751A1Coronavirus vaccineBioNTech SE·Filed 2023·Application pending·0 cites
- 3972US11873478B2Method for reducing immunogenicity of RNABioNTech SE·Filed 2020·Granted Jan 16, 2024·0 cites·20 claims
- 4072US10927181B2Agonistic tumor necrosis factor (TNF) receptor binding agentsBioNTech SE·Filed 2019·Granted Feb 23, 2021·0 cites·20 claims
- 4171US11492628B23′-UTR sequences for stabilization of RNABioNTech SE·Filed 2016·Granted Nov 8, 2022·1 cites·73 claims
- 4271US2025213599A1Formulation for administration of rnaBioNTech SE·Filed 2024·Application pending·0 cites
- 4371US2023190898A1Individualized vaccines for cancerBioNTech SE·Filed 2022·Application pending·0 cites
- 4470US12516333B23′-UTR sequences for stabilization of RNABioNTech SE·Filed 2022·Granted Jan 6, 2026·0 cites·20 claims
- 4570US12263215B2Cytotoxic immunostimulating particles and uses thereofBioNTech SE·Filed 2021·Granted Apr 1, 2025·0 cites·19 claims
- 4670US12168051B2Methods and compositions for stimulating immune responseBioNTech SE·Filed 2022·Granted Dec 17, 2024·0 cites·24 claims
- 4770US11673939B2Compositions and methods for diagnosis and treatment of cancerBioNTech SE·Filed 2019·Granted Jun 13, 2023·1 cites·19 claims
- 4870US2022249372A1Lipid Particle Formulations for Delivery of RNA and Water-Soluble Therapeutically Effective Compounds to a Target CellBioNTech SE·Filed 2022·Application pending·0 cites
- 4970US2024158501A1Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseasesBioNTech SE·Filed 2023·Application pending·0 cites
- 5069US12281322B2RNA replicon for versatile and efficient gene expressionBioNTech SE·Filed 2021·Granted Apr 22, 2025·0 cites·13 claims
Showing the top 50 of 141 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →